Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Moderna, Inc.NASDAQ: MRNA
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $68M rose 30.8% year over year, ahead of the +23.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.
Context
- Depreciation & amortization amounted to 11.1% of revenue in FY2025, up 5.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +30.8% holds above the trailing-twelve-month pace of +23.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 215M USD
- Year-over-year change
- +13.8%
- 4-year CAGR
- -1.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 215M | +13.8% |
| FY2024 | 2024-12-31 | 189M | -69.6% |
| FY2023 | 2023-12-31 | 621M | +78.4% |
| FY2022 | 2022-12-31 | 348M | +50.0% |
| FY2021 | 2021-12-31 | 232M | — |
Depreciation & Amortization vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.6% is the 5th highest of 10, against a peer median of -3.0%.
- Depreciation & amortization amounts to 10.2% of revenue for MRNA, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.58B USD | -3.0% | +9.2% | 10.3% | |
| LTM Jun 2026 | £2.21B GBP | -34.0% | +2.5% | 6.7% | |
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $257M USD | +23.6% | -14.8% | 10.2% | |
| LTM Jun 2026 | $26.8M USD | +40.0% | +38.0% | — | |
| LTM Mar 2026 | €25.21M EUR | +138.6% | +1.1% | 16.1% | |
| LTM Mar 2026 | $22.34M USD | -50.0% | -1.7% | 3.7% | |
| LTM Mar 2026 | $18.23M USD | +41.3% | +46.1% | 27.8% | |
| LTM Mar 2026 | $2.99M USD | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| Peer median (excluding MRNA) | — | -3.0% | +9.2% | 10.3% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| Deferred Income Tax | (318M) | (559M) | 828M | 0 | 0 |
| Stock-Based Compensation | 142M | 226M | 305M | 429M | 483M |
| Change in Working Capital | 1.31B | (3.46B) | (139M) | (78M) | 254M |
| Accounts Receivables | (1.78B) | 1.79B | 493M | 534M | 156M |
| Inventory | (1.39B) | 492M | 747M | 83M | (34M) |
| Accounts Payables | 204M | 240M | 13M | (69M) | (92M) |
| Other Working Capital | 4.28B | (5.98B) | (1.39B) | (626M) | 224M |
| Other Non-Cash Items | 54M | 59M | (19M) | 17M | (3M) |
| Operating Cash Flow | 13.62B | 4.98B | (3.12B) | (3B) | (1.87B) |
| Capital Expenditures | (284M) | (400M) | (707M) | (1.05B) | (192M) |
| Acquisitions (Net) | 0 | 0 | (85M) | 0 | 0 |
| Purchases of Investments | (12.65B) | (11.44B) | (3.78B) | (6.53B) | (5.77B) |
| Sales of Investments | 4.44B | 6.7B | 8.78B | 9.53B | 7.92B |
| Other Investing Activities | (30M) | (40M) | 0 | 0 | (10M) |
| Investing Cash Flow | (8.52B) | (5.18B) | 4.21B | 1.95B | 1.95B |
| Debt Repayment | (140M) | (184M) | (270M) | (10M) | 539M |
| Common Stock Issued | 124M | 65M | 46M | 66M | 35M |
| Common Stock Repurchased | (857M) | (3.33B) | (1.15B) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 19M |
| Financing Cash Flow | (873M) | (3.45B) | (1.38B) | 56M | 593M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 2M |
| Net Change in Cash | 4.22B | (3.64B) | (289M) | (999M) | 668M |
| Free Cash Flow | 13.34B | 4.58B | (3.83B) | (4.06B) | (2.07B) |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.